FPD-MM harbors co-mutations, most commonly on the second allele of RUNX1, and on BCOR, PHF6, K/N-RAS, WT1 or TET2, which confer relative resistance to standard therapy for MDS or AML [2, 5, 7, 8]. This evidence concerns the gene RUNX1 and Miyoshi myopathy.